These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16469003)

  • 1. Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
    Armitage JN; Emberton M
    BJU Int; 2006 Mar; 97(3):439-41. PubMed ID: 16469003
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
    Crawford ED
    BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dalphaz-retard treatment of urination disorders in men and women].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2001; (4):47-8. PubMed ID: 11569237
    [No Abstract]   [Full Text] [Related]  

  • 6. The place of pharmacologic treatment in benign prostatic hyperplasia.
    Caine M
    Semin Urol; 1985 Nov; 3(4):311-6. PubMed ID: 2441447
    [No Abstract]   [Full Text] [Related]  

  • 7. Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?
    Sciarra A
    Eur Urol; 2007 Jun; 51(6):1485-7. PubMed ID: 17275984
    [No Abstract]   [Full Text] [Related]  

  • 8. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 9. Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
    Bèïque L; Por CP; Evans MF
    Can Fam Physician; 1998 Dec; 44():2659-62. PubMed ID: 9870119
    [No Abstract]   [Full Text] [Related]  

  • 10. Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2004 Jan; 46(1173):1-2. PubMed ID: 14691408
    [No Abstract]   [Full Text] [Related]  

  • 11. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alfuzosin in the treatment of benign prostatic hypertrophy].
    Jardin A
    J Urol (Paris); 1993; 99(6):308-10. PubMed ID: 7516375
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
    Mensink HJ
    Prog Clin Biol Res; 1994; 386():285-9. PubMed ID: 7528396
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of apha-blockaders in the treatment of prostatism].
    Penders L; Bouffioux C
    Acta Urol Belg; 1983; 51(4):518-31. PubMed ID: 6196958
    [No Abstract]   [Full Text] [Related]  

  • 15. [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
    Hansen BJ; Meyhoff HH
    Ugeskr Laeger; 1992 Feb; 154(6):361-2. PubMed ID: 1371629
    [No Abstract]   [Full Text] [Related]  

  • 16. Benign prostatic hyperplasia.
    Doherty AP
    Hosp Med; 2003 Feb; 64(2):114. PubMed ID: 12619342
    [No Abstract]   [Full Text] [Related]  

  • 17. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of various alpha1-adrenergic receptor antagonists on pupillary dilation.
    Arikan G; Demir O; Yaman A; Bozkurt O; Saatci AO; Durak I; Esen A
    Ann Ophthalmol (Skokie); 2008; 40(1):19-21. PubMed ID: 18556976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The objective of medical treatment: relieve the symptoms or stop the course?].
    Desgrandchamps F
    Ann Urol (Paris); 2006 Mar; 40 Spec No 1():14-6. PubMed ID: 16649585
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment to short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gravas S
    Int J Urol; 2010 Oct; 17(10):875. PubMed ID: 20887633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.